Bilateral breast multiple myeloma: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Bilateral breast multiple myeloma: a case report
Cyrus KM Mo, MB, ChB, FRCR1; Alta YT Lai, FRCR, FHKAM (Radiology)1; Sherwin SW Lo, FRCR, FHKAM (Radiology)2; TS Wong, MB, BS3; Wendy WC Wong1, FRCR, FHKAM (Radiology)1
1 Department of Radiology, Pamela Youde Nethersole Eastern Hospital, Hong Kong
2 Department of Radiology, Gleneagles Hospital, Hong Kong
3 Department of Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong
 
Corresponding author: Dr Cyrus KM Mo (mkm463@ha.org.hk)
 
 Full paper in PDF
 
Introduction
Multiple myeloma (MM) is a malignant disorder characterised by excessive proliferation of single clonal plasma cells derived from B cells in the bone marrow with increased formation of monoclonal immunoglobulins.1 Multiple myeloma may involve extramedullary organs or soft tissues (extramedullary plasmacytoma), commonly in the upper aerodigestive tract with a predilection for the head and neck.1 Breast plasmacytoma is very rare. We present a case of MM with extensive extramedullary involvement including bilateral breasts, and mainly focus on the imaging features of breast plasmacytoma across multi-modalities.
 
Case report
A 59-year-old female presented for scheduled ultrasound scan of abdomen for follow-up of a complicated renal cyst in December 2019. She had a previous history of diabetes mellitus, hypertension, hyperlipidaemia and hepatitis B infection. She was diagnosed with MM 10 years previously and had previously failed hematopoietic stem cell transplantation. Ultrasound scan revealed an enlarged hypoechoic nodule in the liver that corresponded to the liver lesion detected on earlier computed tomography (CT) urogram. She also complained of a palpable nodule in the right lower quadrant of the abdomen, present for a few months. Magnetic resonance imaging (MRI) with contrast of liver was arranged to assess the liver lesion and abdominal wall nodule.
 
The MRI 1 month later showed significant enlargement of the liver lesion with heterogeneous contrast enhancement and restricted diffusion. No definite contrast washout was demonstrated in the portovenous phase. The nodule in the right lower quadrant of the abdominal wall demonstrated contrast enhancement and restricted diffusion as well. Features of both lesions were suggestive of malignancy. The MRI also revealed a 1.3 cm T1 isointense T2 hyperintense contrast enhancing nodule with restricted diffusion in the outer lower quadrant of the left breast (Fig 1).
 

Figure 1. Selected magnetic resonance imaging images: (a) pre-contrast T1-weighted axial image, (b) post-contrast T1-weighted axial image, (c) T2-weighted fat-saturated axial image, (d) diffusion weighted image, and (e) apparent diffusion coefficient. The lesion (arrowheads) in the lower outer quadrant of the left breast demonstrated homogeneous contrast enhancement and restricted diffusion
 
Ultrasound-guided fine needle aspiration of the right lower quadrant abdominal wall nodule was performed in February 2020. The pathological diagnosis was plasmacytoma.
 
Dual-tracer positron emission tomography (PET)/CT was performed in early March 2020 at a private institution to assess disease involvement. There were multiple acetate (Ac) and fludeoxyglucose (FDG)-avid soft tissue nodules in bilateral breasts, measuring up to 1.5 × 1.4 cm with FDG maximum standard unit value (SUVmax) 8.4 and Ac SUVmax 5.0 in left breast (Fig 2a) and 1.4 × 1.0 cm with FDG SUVmax 7.0 and Ac SUVmax 6.6 in right breast. There were a few left axillary level I lymph nodes measuring up to 0.9 × 0.8 cm with FDG SUVmax 3.3 and Ac SUVmax 3.9.
 

Figure 2. Selected mammography, ultrasound image, fludeoxyglucose (FDG) positron emission tomography/computed tomography fusion image and histopathological slides of left breast lesion. (a) A focal FDG-avid lesion in the left breast at the 3:00 position. (b) Craniocaudal view of left mammography. Several oval ill-defined equal-to-high density lesions were detected in the left breast. No associated microcalcification was identified. (c) The largest mass in the left breast located at the 3:00 position 3 cm from the nipple was evident as an ill-defined heterogeneous mass with hypoechoic and echogenic areas. (d) Light photomicrograph of haematoxylin and eosin stain on 400 x magnification. Tumour cells possess eosinophilic cytoplasm with perinuclear hof and hyperchromatic nuclei with occasional nucleoli. (e & f) Light photomicrograph of immunohistochemistry staining on 400 x magnification. Tumour cells are negative for AE1/AE3 (pancytokeratin) and positive for CD138 (Syndecan-1)
 
Bilateral mammography and breast ultrasound were arranged in early April 2020 to assess bilateral breast lesions. There were multiple oval and ill-defined equal-to-high density lesions in both breasts. The largest lesion located at the upper outer quadrant of the right breast measured 3.6 × 2.8 cm and was palpable. No associated suspicious microcalcifications were detected. There was no architectural distortion, skin thickening or enlarged lymph nodes on mammography (Fig 2b).
 
Subsequent breast ultrasound on the same section revealed scattered oedematous areas in both breasts. A heterogeneous mass with hypoechoic and echogenic areas was detected in the left breast at a 3:00 position, 3 cm from the nipple (Fig 2c). Posterior enhancement was evident. This mass corresponded to the lesion detected on previous MRI. The size was 2.7 × 2.5 × 2.5 cm. There was interval enlargement compared with previous MRI (which was 1.3 cm). Multiple hypoechoic, echogenic, and heterogeneous masses and nodules were identified in other areas of both breasts. The largest one in the right breast located at a 9:00 position 5 cm from the nipple measured 4.5 × 2.6 × 4.1 cm. There was an irregular hypoechoic enlarged left axillary lymph node with loss of fatty hilum. Ultrasound-guided fine needle aspiration of this node and core biopsies of the dominant masses in each breast were performed in the same section. The pathological diagnoses of the breast masses and left axillary lymph node were consistent with plasmacytoma (Fig 2d-f). Two weeks later (mid-April 2020), the patient was admitted with multilobar pneumonia and severe metabolic acidosis and disseminated intravascular coagulation. Unfortunately, she passed away 4 days later.
 
Discussion
Breast plasmacytoma is extremely rare. Approximately 50 cases have been reported in the literature since 1925.2 3 4 5 The prevalence is unknown. Surov et al6 reported a prevalence of 1.5% for breast plasmacytoma among patients with plasmacytoma in their institution. Involvement of the breast was a secondary event of MM in 85% and more than half of the lesions were unilateral.6
 
There are some differences in the ultrasonographic features of breast MM between this case and those reported in the literature. For the cases described by Ali et al2 and Park5, breast MM was revealed as a well-defined oval hypoechoic mass on ultrasound. In our patient, it was an indistinct oval heterogeneous mass with hypoechoic and echogenic areas.
 
Compared with typical primary breast cancer (invasive ductal carcinoma) that is usually revealed as an irregular spiculated high-density mass on mammogram and an anti-parallel hypoechoic irregular spiculated mass on ultrasound, there are no characteristic imaging features of breast MM. On mammography, it can present as a single or multiple high-density round or oval lesion(s) that is/are circumscribed or ill-defined.2 It can show as diffuse infiltration. Association with microcalcifications is rarely reported. On ultrasound, the features are well-defined echo-poor, hypoechoic, or hyperechoic solid masses with hypervascularity.2 Mixed hypo- to hyper-echoic masses with indistinct margins are also possible. Posterior acoustic features are variable. Posterior acoustic enhancement can be evident but absence of acoustic transmission or even posterior acoustic shadowing has been reported in some cases.
 
There are limited case reports of MRI and PET/ CT features of breast MM. On MRI, it shows as a T1-weighted intermediate to hypointense T2-weighted hyperintense lesion with homogeneous or rim enhancement. Restricted diffusion and early rapid contrast enhancement with washout kinetics are the reported features.5 It appears as a homogeneous soft tissue lesion with high FDG uptake on PET/CT.
 
No case report has discussed the features of breast MM on dual-tracer PET/CT. It was revealed as an Ac-avid lesion in our patient, indicative of high metabolism of malignant plasma cells. There are provisos in this case report. The MRI protocols did not relate specifically to breast imaging and contrast kinetics was not performed.
 
Conclusion
There are no specific radiological features of breast MM. In bilateral multiple breast masses, the differential diagnoses are lymphoma, metastasis, synchronous primary breast cancer, secondary involvement of haematological disorder or benign conditions such as fibroadenoma. Biopsy for histopathological diagnosis is advised.
 
Author contributions
Concept or design: CKM Mo, AYT Lai.
Acquisition of data: SSW Lo, TS Wong.
Analysis or interpretation of data: SSW Lo, TS Wong.
Drafting of the manuscript: CKM Mo, AYT Lai, WWC Wong.
Critical revision of the manuscript for important intellectual content: CKM Mo, AYT Lai, WWC Wong.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
The authors have no conflicts of interest to disclose.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The patient was treated in accordance with the Declaration of Helsinki. Informed consent for publication was unobtainable from the deceased patient's next-of-kin despite all reasonable efforts.
 
References
1. Angtuaco EJ, Fassas AB, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnostic imaging. Radiology 2004;231:11-23. Crossref
2. Ali HO, Nasir Z, Marzouk AM. Multiple myeloma breast involvement: a case report. Case Rep Radiol 2019;2019:2079439. Crossref
3. Kaviani A, Djamali-Zavareie M, Noparast M, Keyhani-Rofagha S. Recurrence of primary extramedullary plasmacytoma in breast both simulating primary breast carcinoma. World J Surg Oncol 2004;2:29. Crossref
4. Lee HS, Kim JY, Kang CS, Kim SH, Kang JH. Imaging features of bilateral breast plasmacytoma as unusual initial presentation of multiple myeloma: case report and literature review. Acta Radiol Short Rep 2014;3:2047981614557666. Crossref
5. Park YM. Imaging findings of plasmacytoma of both breasts as a preceding manifestation of multiple myeloma. Case Rep Med 2016;2016:6595610. Crossref
6. Surov A, Holzhausen HJ, Ruschke K, Arnold D, Spielmann RP. Breast plasmacytoma. Acta Radiol 2010;51:498-504. Crossref

Abscess formation following accidental ingestion of fish bone with migration to the submandibular gland: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Abscess formation following accidental ingestion of fish bone with migration to the submandibular gland: a case report
Alan TL Lau, MB, ChB1; Raymond KY Tsang, MS, FHKAM (Otorhinolaryngology)2; Nikie HY Sun, MB, ChB3
1 Department of Otorhinolaryngology, Queen Mary Hospital, Hong Kong
2 Department of Surgery, The University of Hong Kong, Hong Kong
3 Department of Otorhinolaryngology, Queen Mary Hospital, Hong Kong
 
Corresponding author: Dr Alan TL Lau (ltl194@ha.org.hk)
 
 Full paper in PDF
 
Introduction
Deep neck space infection is associated with significant morbidity and mortality, with the submandibular space being a common site of infection. Causes include odontogenic infections, submandibular sialadenitis, lymphadenitis, trauma, or surgery. This case report describes an uncommon cause of fish bone migration to the submandibular gland with consequent abscess formation. Apart from fish bones, a variety of foreign bodies in salivary glands has been described in previous case reports, including toothbrush bristles, slivers of fingernails, wood splinters, hairs or blades of grass.1
 
Case report
A 38-year-old woman with good past health accidentally ingested a fish bone in September 2020. She subsequently developed a sore throat, right neck pain and swelling. She attended the emergency department at Queen Mary Hospital 2 days later due to progressive symptoms. On admission, she had a fever of 38.1°C with blood pressure 161/80 mm Hg and pulse 113 beats per minute. Physical examination revealed a palpable tender right upper neck swelling. The right floor of mouth was oedematous and tender on palpation. At the opening of the Wharton’s duct, no foreign body was palpable, and no pus was evident. Flexible laryngoscopy of the pharynx and larynx was normal. An urgent computer tomography with contrast revealed a 14-mm linear foreign body at the right submandibular gland with surrounding right submandibular abscess (Fig 1).
 

Figure 1. (a) Axial contrast computer tomography of the neck. The white arrow indicates the 14 mm linear opacity at the right submandibular gland with surrounding submandibular abscess. (b) Coronal contrast computer tomography of the neck showing right submandibular abscess (white arrow)
 
Emergency exploration under general anaesthesia was performed. First, transoral exploration was performed through an incision at the right posterolateral floor of mouth to retrieve the foreign body and drain the pus. In view of negative transoral exploration, transcervical exploration was performed. An abscess cavity was revealed at the medial surface of the right submandibular gland and pus was drained. Right submandibular sialoadenectomy was performed and subsequently a 14-mm fish bone was found impacted at the medial surface of the right submandibular gland (Fig 2). A 15Fr silicon drain was inserted to the wound bed. The patient was monitored in the intensive care unit postoperatively and was extubated the day following surgery. Intravenous amoxicillin-clavulanate (1.2 grams every 8 hours) was prescribed. Culture of pus was negative. Fever and neck swelling subsided and the drain was removed on postoperative day 3. The patient was discharged on postoperative day 5 with diet well tolerated. At 2-week follow-up, the neck and oral wound were well healed. The hypoglossal nerve, lingual nerve and facial nerve function was intact.
 

Figure 2. Specimen of right submandibular gland and fish bone. The length of the fish bone was 14 mm
 
Discussion
A fish bone can usually be retrieved easily via endoscopy when lodged in the oral cavity, pharynx, or oesophagus. Nonetheless, some patients with a negative endoscopic finding may present later with neck swelling and fever that may indicate a deep neck space infection or migration of the foreign body to the neck. Extraluminal migration of foreign vein, subcutaneous neck, the thyroid gland, and the cervical spine has been reported in previous case reports.2
 
Migration of fish bone to the submandibular gland is uncommon. There have been two hypotheses for such an event: direct trauma and retrograde migration. Some theories suggest that continuous flow of saliva from ducts into the oral cavity, the duct orifice being mobile and able to twist in all directions, and small diameter of duct at the orifice render retrograde migration rare.1 In a previous study of sialoendoscopic assessment of patients with suspected obstruction in the ductal system of salivary glands, 3.9% had sialoliths related to fish bone, with the left submandibular gland being the dominant site (92.3%). Compared with the submandibular gland, foreign body at the parotid glands is much less common.3
 
Foreign body at the submandibular gland can have a variety of consequences. A patient with acute right submandibular sialadenitis due to an impacted fish bone has been reported who presented with tender submandibular swelling.4 The patient had no recall of foreign body ingestion. Plain radiograph of the neck revealed a radiopaque foreign body. The infection eventually required antibiotic treatment and submandibular gland excision, with identification of a fish bone at the excised gland. Another patient presented with chronic sialadenitis. A fish bone–induced sialolith was successfully removed with sialoendoscopy.5 A third patient presented with deep neck space infection with abscess formation, as in our patient.
 
Different techniques have been applied to remove foreign body from the submandibular gland.6 For sialoendoscopy, a higher success rate has been observed with foreign bodies in the distal duct while those located in the more proximal part and secondary branches of the Wharton’s duct have been difficult to remove. Surgery may be required if endoscopic treatment is not suitable, either using a transoral approach or transcervical approach with submandibular gland sialadenectomy. In this case report, a transcervical approach was eventually adopted.
 
Conclusion
The mainstay of treatment for submandibular abscess is airway protection, antibiotic treatment, and surgical drainage. Timely diagnosis and treatment are key to success. Despite being a rare cause, submandibular gland foreign body complicated by abscess formation should be considered as a differential diagnosis in patients with submandibular swelling who report swallowing of a fish bone.
 
Author contributions
Concept or design: RKY Tsang.
Acquisition of data: NHY Sun.
Analysis or interpretation of data: ATL Lau.
Drafting of the manuscript: ATL Lau.
Critical revision of the manuscript for important intellectual content: RKY Tsang.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Acknowledgement
Dr Joseph CK Chung and Dr Sylvia SY Yu have made a substantial contribution in terms of academic advice to the publication of this case report.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The study was conducted in accordance with guidelines of the Hong Kong West Cluster Research Ethics Committee (IRB Ref No.: UW21-094). Informed consent was obtained from the patient.
 
References
1. Su YX, Lao XM, Zheng GS, Liang, LZ, Huang XH, Liao GQ. Sialoendoscopic management of submandibular gland obstruction caused by intraglandular foreign body. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:e17-21. Crossref
2. Hsu CL, Chen CW. A prolonged buried fish bone mimicking Ludwig angina. Am J Otolaryngol 2011;32:75-6. Crossref
3. Xie L, Zheng L, Yu C, et al. Foreign body induced sialolithiasis treated by sialoendoscopic intervention. J Craniofac Surg 2014;25:1372-5. Crossref
4. Riccio FJ, Scavo VJ. Unusual foreign body etiology of sialadenitis. Arch Otolaryngol 1967;86:210-2. Crossref
5. Iwai T, Sugiyama S, Hayashi Y, et al. Sialendoscopic removal of fish bone-induced sialoliths in the duct of the submandibular gland. Auris Nasus Larynx 2018;45:343-5. Crossref
6. Li P, Zhu H, Huang D. Detection of a metallic foreign body in the Wharton duct: a case report. Medicine (Baltimore) 2018;97:e12939. Crossref
 

A rather difficult case of acute generalised exanthematous pustulosis: would colchicine be a treatment option?

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
A rather difficult case of acute generalised exanthematous pustulosis: would colchicine be a treatment option?
Rabia Oztas Kara, MD; Bahar Sevimli Dikicier, MD; Mahizer Yaldiz, MD; Hande Tekmenler, MD
Department of Dermatology, Sakarya University Faculty of Medicine, Sakarya, Turkey
 
Corresponding author: Dr Rabia Oztas Kara (r.oztas.kara@gmail.com)
 
 Full paper in PDF
 
Case report
A 24-year-old lactating female patient presented with redness, burning, and rash on the face and body on the fifth day of hydroxychloroquine (HCQ) treatment, prescribed after diagnosis of coronavirus disease 2019 infection. Physical examination revealed numerous non-follicular pustular lesions on an erythematous background that started on the face and neck and extended to the whole body, especially in the folds and extremities, and in the palmoplantar regions (Fig 1a). Conjunctival involvement was also evident. Examination was otherwise unremarkable and the patient was afebrile.
 

Figure 1. (a) Numerous non-follicular pustules on an erythematous base on the leg. (b) Non-follicular pustules recurring in areas of desquamation. (c) Complete recovery after desquamation
 
Laboratory examinations were likewise unremarkable (Table). Histopathological examination of punch biopsy of the leg lesions, subcorneal pustule formation in the epidermis, oedema in the papillary dermis, and lymphocytic infiltration in the upper dermis was performed (Fig 2). There was no individual or family history of psoriasis, and the patient denied taking any medication except HCQ in the last 3 months. Based on these findings, the patient was diagnosed with HCQ-induced (acute generalised exanthematous pustulosis [AGEP]). Intravenous methylprednisolone 60 mg/day, etodolac, topical methylprednisolone, and moisturiser were prescribed. An initial partial response was achieved but on the 15th day of treatment, pustular lesions, itching, and complaints of burning recurred and the patient developed a fever of 38°C (Fig 1b). Blood cultures grew Staphylococcus aureus, sensitive to ciprofloxacin. Systemic ciprofloxacin 750 mg twice a day (1500 mg daily) was started with the addition of 0.5 mg colchicine thrice a day (1.5 mg daily). Her general condition improved and the skin lesions completely regressed with desquamation (Fig 1c). Systemic methylprednisolone treatment was tapered and stopped. Colchicine treatment was continued for 1 month and the dose then decreased to 0.5 mg twice a day for a further month before being stopped. The patient continues to attend for follow-up and remains well. A patch test for HCQ is planned when lactation stops.
 

Table. Laboratory blood test results
 

Figure 2. Subcorneal pustule formation in the epidermis, oedema in the papillary dermis, and perivascular inflammation accompanied by eosinophils and neutrophils in the upper dermis (a: ×10, b: ×40)
 
Discussion
Drugs constitute 90% of the aetiology of AGEP. The remaining 10% are due to infection. Although the pathogenesis of AGEP is not fully understood, the accumulation of cytokines released by helper T cells and drug-induced antigen-antibody complexes in the skin is blamed.1
 
The cutaneous side-effects of hydroxychloroquine include AGEP, urticaria, pruritus, xerosis, maculopapular rash, psoriasis, erythroderma, Stevens–Johnson syndrome, hair loss, and hair whitening.2 Since hydroxychloroquine is a weak base with a long half-life, it passes into breast milk in minimal amounts.
 
In previously reported cases of HCQ-induced AGEP, the duration of exposure to HCQ was reported to be 2 to 30 days prior to symptom onset3 and time to recovery after stopping HCQ has been reported to be 7 to 81 days.4 The long persistence of symptoms can be explained by the long half-life of HCQ, approximately 40 to 50 days.5
 
Acute generalised exanthematous pustulosis cases due to HCQ have been reported during the pandemic. The typical features of these cases are a more prolonged course and a need for systemic steroid treatment. In this patient, colchicine was started because a complete response was not obtained with systemic corticosteroid treatment.
 
Colchicine suppresses inflammation at many stages. It has an antimitotic impact by binding to tubulin, preventing its polymerisation into new microtubules, inhibits neutrophil chemotaxis, and reduces free oxygen radical production by neutrophils. It is more useful in the treatment of neutrophilic dermatoses such as pustular conditions with predominant neutrophilic infiltrates, eg, pustular psoriasis. For this reason and the lack of response to systemic corticosteroid treatment, colchicine was added to our patient’s treatment regimen.
 
We conclude that colchicine may be a treatment option for AGEP, a rare side-effect of HCQ, especially when it is resistant to systemic corticosteroid. It can also be used as an effective treatment during lactation due to its better safety profile.
 
Author contributions
Concept or design: All authors.
Acquisition of data: R Oztas Kara, H Tekmenler.
Analysis or interpretation of data: All authors.
Drafting of the manuscript: R Oztas Kara, H Tekmenler.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
The authors have no conflicts of interest to disclosure.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The patient was treated in accordance with the Declaration of Helsinki. The patient provided informed consent for the treatment/procedures and consent for publication.
 
References
1. Halevy S, Kardaun SH, Davidovici B, Wechsler J, EuroSCAR and RegiSCAR Study Group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 2010;163:1245-52. Crossref
2. Salido M, Joven B, D’cruz, DP, Khamashta MA, Hughes GR. Increased cutaneous reactions to hydroxychloroquine (Plaquenil) possibly associated with formulation change: comment on the letter by Alarcón. Arthritis Rheum 2002;46:3392-6. Crossref
3. Liccioli G, Marrani E, Giani T, Simonini G, Barni S, Mori F. The first pediatric case of acute generalized exanthematous pustulosis caused by hydroxychloroquine. Pharmacology 2019;104:57-9. Crossref
4. Pearson KC, Morrell DS, Runge SR, Jolly P. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Cutis 2016;97:212-6.
5. İslamoğlu ZG, Karabağli P. A case of recalcitrant acute generalized exanthematous pustulosis with Sjogren’s syndrome: successfully treated with low-dose cyclosporine. Clin Case Rep 2019;7:1721-4. Crossref
 

Importance of cascade family screening and precision medicine for patients with familial hyperkalaemia: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Importance of cascade family screening and precision medicine for patients with familial hyperkalaemia: a case report
HY Lam, MB, BS1; Eugene YH Chan, MRCPCH (UK), FHKAM (Paediatrics)2; Joanna YL Tung, MB, BS, MRCPCH (UK)2; Samantha LK Lee, MB, BS, MPH (HKU)2 Jasmine LF Fung, BBiomedSc3; Mianne Lee, MSc3; Brian HY Chung, MD2,3; Alison LT Ma, MRCPCH (UK), FRCPCH (UK)2
1 Department of Paediatrics and Adolescent Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong
2 Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong
3 Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong
 
Corresponding author: Ms HY Lam (charlottelamhy@gmail.com)
 
 Full paper in PDF
 
Case report
The patient was the only child of a non-consanguineous Chinese couple and was born at full term by normal vaginal delivery with a birth weight of 2.85 kg. She had good past health except for admission for a reflex-anoxic attack at age 7 months. Physical examination at that time was unremarkable with normal growth parameters and normal blood pressure for her age. Investigations showed normal anion gap metabolic acidosis and hyperkalaemia with a potassium of 7.1 mmol/L but normal serum sodium and renal function. In view of the biochemical findings, the provisional diagnosis was type IV renal tubular acidosis. Fludrocortisone was started with sodium bicarbonate and furosemide and a low potassium diet commenced. However, recurrent episodes of hyperkalaemia continued despite good compliance, requiring potassium binder and medication adjustment.
 
In December 2019, because of the suboptimal control of hyperkalaemia, with a fluctuating potassium level of 4.5 to 6.4 mmol/L, the patient was referred to our unit at age 10 years. Her blood pressure remained normal throughout. Blood test results revealed hyperreninaemic hyperaldosteronism with elevated supine renin at 5.59 ng/mL/hr (reference: 0.15-2.33 ng/mL/hr) and elevated aldosterone at 785 pmol/L (reference: 28-444 pmol/L). Pseudohypoaldosteronism type I was suspected initially.
 
Trio whole exome sequencing revealed a paternally inherited novel missense change in WNK4:NM_032387.5:c.1685A>G:p.(Glu562Gly), confirming a diagnosis of pseudohypoaldosteronism type IIB. This patient was coincidentally part of a larger whole exome sequencing cohort where the study was focused on cost-effectiveness of rapid whole exome sequencing.1 The patient was treated with oral 25 mg hydrochlorothiazide once daily and remained stable with normal growth and development. The serum potassium and blood pressure were well controlled and there were no dental or renal complications on follow-up examination.
 
Family cascade screening revealed that her father, paternal grandmother, and paternal aunt had hyperkalaemia. All were subsequently confirmed to have the same mutation (Fig 1). Retrospectively, the father had provided a history of kidney stone, hyperkalaemia, hypercalciuria and hypertension since age 35 years. He was found to have a serum potassium level of 7 mmol/L during the cascade screening. Although asymptomatic, his electrocardiogram already showed hyperkalaemic changes with tented T waves and high blood pressure at 176/116 mmHg. He was started on hydrochlorothiazide with normalisation of both serum potassium and blood pressure a few days later. The paternal grandmother also had a history of hyperkalaemia and partially controlled hypertension. The paternal aunt was asymptomatic with good past health but was found to be hypertensive and hyperkalaemic on screening. They were also started on hydrochlorothiazide with good response.
 

Figure 1. Pedigree of the family affected with Gordon’s syndrome
 
Discussion
We report a Chinese family with the rare cause of hyperkalaemia and type IV renal tubular acidosis due to an autosomal dominant condition called Pseudohypoaldosteronism type II (PHAII). Whole exome sequencing established the diagnosis in our index patient, and subsequently, other affected family members were identified through cascade family screening.
 
Pseudohypoaldosteronism type II, also referred to as familial hyperkalaemic hypertension, or Gordon’s syndrome, was first described in 1964.2 By 2013, around 100 to 200 individuals and families with PHAII had been reported.3 Hyperkalaemia with normal renal function is the main characteristic. Other common features include metabolic acidosis, diminished renal potassium excretion, hypercalciuria, low plasma renin/aldosterone levels and hypertension. Short stature and dental abnormalities have also been reported.4
 
Mutation in the gene encoding with-no-lysine kinase 4 (WNK4), one of the novel proteins involved in the pathogenesis of PHAII, was identified in our patient. Other identified genes include WNK1, kelch-like 3 and cullin 3.3 The WNK4 is one of the WNK isoforms that regulates sodium-chloride co-transporter (NCC) in the distal convoluted tubule. Without the inhibitory effect of normal WNK4, sodium and chloride reabsorption are increased via the NCC, leading to volume expansion and consequent hypertension. The NCC is more proximal to the epithelial sodium channel at the distal convoluted tubule. Excessive sodium reabsorption at NCC results in reduced sodium delivery to epithelial sodium channels for potassium secretion at Na+/K+ exchange.3 This theory explains why thiazide is effective in PHAII as it inhibits NCC. Increased intracellular sodium due to increased NCC activity will cause decreased basolateral Na+/Ca2+ exchange that may result in hypercalciuria as in the father of our index patient. It has been suggested that mutant WNK4 decreases the activity of renal outer medullary potassium channels more than wild-type WNK4. Another proposed mechanism of this Chloride Shunt Syndrome is increased chloride reabsorption through paracellular pathways due to the mutant WNK4, resulting in reduced negativity at the distal epithelial sodium channel.3 These can all lead to reduced urinary potassium excretion (Fig 2) with consequent increase in serum potassium. With increased potassium retention, the excretion of hydrogen is impaired leading to metabolic acidosis. Hypertension tends to appear later in life, in men aged 30-40 years and in women aged 40-50 years,5 but can also be absent in 20% of cases.3
 

Figure 2. Proposed mechanisms of hyperkalaemia in pseudohypoaldosteronism type II
 
In this patient, pseudohypoaldosteronism type I was initially suspected in view of the grossly elevated renin and aldosterone levels. However, the age of disease onset and normal sodium level were atypical. The elevated renin and aldosterone levels in our patient could be explained by the use of furosemide that could have resulted in hypovolaemia and thus activation of the renin-angiotensin-aldosterone-system. This made the interpretation of the biochemical picture challenging. In this regard, the use of genetic testing demonstrated superiority in guiding the diagnosis of these chronic conditions in which a classic clinical phenotype had already been modified by existing treatments.
 
Our case also highlights the importance of cascade family screening. The three family members were identified to have potentially life-threatening hyperkalaemia and were treated promptly based on their genetic mutation. Affected patients will continue regular follow-up with serum electrolyte and blood pressure monitoring. With specific treatment, the disease can be well-controlled. This case illustrates the importance of precision medicine, as well as its benefits of personalised and targeted interventions.
 
Author contributions
Concept or design: HY Lam, ALT Ma.
Acquisition of data: YH Chan, ALT Ma.
Analysis or interpretation of data: All authors.
Drafting of the manuscript: HY Lam, EYH Chan.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Funding/support
The genetic investigation was supported by the Health and Medical Research Fund (HMRF) by the Hong Kong Food and Health Bureau (Project Ref No: 06172806) and The Society for the Relief of Disabled Children.
 
Ethics approval
The patient was treated in accordance with the tenets of the Declaration of Helsinki. The father of the patient consented verbally to publication of this case report.
 
References
1. Chung CC, Leung GK, Mak CC, et al. Rapid whole-exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. Lancet Reg Health West Pac 2020;1:100001. Crossref
2. Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 1964;2:305-6. Crossref
3. Healy JK. Pseudohypoaldosteronism type II: history, arguments, answers, and still some questions. Hypertension 2014;63:648-54. Crossref
4. Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 1986;8:93-102. Crossref
5. Farfel A, Mayan H, Melnikov S, Holtzman EJ, Pinhas-Hamiel O, Farfel Z. Effect of age and affection status on blood pressure, serum potassium and stature in familial hyperkalaemia and hypertension. Nephrol Dial Transplant 2011;26:1547-53. Crossref

Acquired C1-inhibitor deficiency in chronic lymphocytic leukaemia: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Acquired C1-inhibitor deficiency in chronic lymphocytic leukaemia: a case report
Andy SO Tang, MD, MRCP (UK)1; QY Wong, MB, BS2; ST Yeo, BPharm (Hon)2; Jenny TH Lee, MB, BS3; TS Leong, MB, BS, MRCP (UK)4; LP Chew, MD, FRCP (UK)4
1 Haematology Unit, Department of Internal Medicine, Miri Hospital, Ministry of Health, Sarawak, Malaysia
2 Department of Internal Medicine, Miri Hospital, Ministry of Health, Sarawak, Malaysia
3 Department of Pathology, Sarawak General Hospital, Ministry of Health, Sarawak, Malaysia
4 Haematology Unit, Department of Internal Medicine, Sarawak General Hospital, Ministry of Health, Sarawak, Malaysia
 
Corresponding author: Dr Andy SO Tang (andytangsingong@gmail.com)
 
 Full paper in PDF
 
Case report
Acquired C1-inhibitor deficiency is a rare disorder with varying manifestations and an estimated prevalence of 1 per 100 000 to 500 000 population.1 We present a case of acquired angio-oedema that manifested after a diagnosis of chronic lymphocytic leukaemia (CLL).
 
In June 2017, a 60-year-old man who was previously healthy was found to have lymphocytosis on routine health screening. Physical examination showed multiple lymph nodes with no hepatosplenomegaly. A lymph node biopsy was consistent with small lymphocytic lymphoma. Bone marrow examination revealed small mature-looking lymphocytes with a background of smudge cells. The leukaemia cells co-expressed the CD5 antigen and B-cell surface antigens, with restricted kappa immunoglobulin light chain expression. Fluorescence in situ hybridisation analysis demonstrated a homozygous 13q14.2 gene deletion. Serum kappa and lambda free light chain (FLC) results were 99.50 mg/L (reference 6.70-22.40 mg/L) and 12.50 mg/L (reference 8.30-27.00 mg/L), respectively, with a kappa to lambda ratio of 7.96. Beta-2 microglobulin level was 4.64 mg/L (reference 1.09-2.53 mg/L). The patient screened seronegative for human immunodeficiency virus, syphilis, and hepatitis B and C. Overall findings were consistent with a diagnosis of CLL Rai stage II (Binet stage B), with Eastern Cooperative Oncology Group performance status zero. A ‘wait and watch’ approach was adopted initially until mid-2018 when the patient started to report fatigue and absolute lymphocyte count doubled in less than 6 months. Owing to limited resources, the patient was given weekly intravenous rituximab (500 mg) but developed herpes zoster infection after two cycles. Treatment was changed to chlorambucil (8 mg once daily) and prednisolone (20 mg once daily) for 10 days per cycle, repeating every 28 days, with acyclovir prophylaxis.
 
At 1 year after this treatment started, the patient presented with an acute event of angio-oedema that began as a tingling around his face and mouth similar to a bee sting and swelling of his lips and tongue (Fig 1), sparing the larynx, abdomen, extremities, and genital involvement. There were no identifiable inciting episodes. He denied intake of angiotensin-converting enzyme inhibitors, traditional medications, or over-the-counter drugs. He had no history of atopy or angio-oedema.
 

Figure 1. (a, b) Photographs showing 60-year-old man with angio-oedema of the lips and tongue
 
The patient remained well until early 2020 when he presented with similar episodes of angio-oedema that recurred on three occasions. A complete workup revealed a C1 esterase inhibitor antigen level of 4 mg/dL (reference 19-37 mg/dL) with function being 9% (reference <66%). Complement C1q level measured using radial immunodiffusion assay was undetectable with low complement 3 and 4 [0.29 g/L (reference value 0.9-1.8 g/L), <0.02 g/L (reference value 0.15-0.45 g/L), respectively]. Owing to restricted resources, anti-C1 inhibitor antibodies and monoclonal component isotypes were unavailable. Autoimmune screening (antinuclear antibody and rheumatoid factor) and serum cryoglobulin were negative. Skin biopsy showed features of angio-oedema without atypical lymphocytes (Fig 2). During the fourth acute attack of angio-oedema, the patient was given tranexamic acid and danazol and symptoms completely resolved within 24 hours.
 

Figure 2. Skin punch biopsy showed solar elastosis in background of prominent oedema (H&E stain, ×200)
 
The overall clinical manifestations and laboratory findings were consistent with the diagnosis of acquired angio-oedema due to C1 deficiency in association with CLL. We decided to initiate chemotherapy—rituximab, cyclophosphamide, vincristine, and prednisolone. After two cycles, the patient developed urticaria vasculitis over his limbs that responded to cetirizine and resolved completely after completing six cycles of chemotherapy. C1 esterase inhibitor functional assay normalised. He remained free of any recurrent angio-oedema and urticaria during the 1-year follow-up period. He was able to resume work and could live independently.
 
Discussion
Angio-oedema can be hereditary or acquired. The latter often presents after the fifth decade of life with no family history.1 Symptom onset and absence of family history led to a diagnosis of acquired angio-oedema in our patient due to C1 esterase inhibitor deficiency. The median time to diagnosis is reported to vary between 10 months and 10 years.2 Our patient was diagnosed 9 months after symptom onset and during the third episode of angio-oedema. To the best of our knowledge, only about 20 cases of CLL have been reported to be associated with angio-oedema.2 Many diseases are reported to be associated with acquired angio-oedema, with lymphoproliferative disorders and B-cell malignancies the most common.3
 
In acquired angio-oedema, C1 esterase inhibitor protein level is decreased due to excessive consumption, or may be dysfunctional due to the presence of antibodies against C1 inhibitor, leading to defective inhibition of the complements and kinin system. This results in exaggerated response in the classic complement pathway and production of bradykinin leading to angio-oedema, in which C1q and C4 level is low, as in our case.2 Our patient also developed urticaria vasculitis. This was likely due to C1q depletion and low complement, as previously reported.2 Urticaria vasculitis, which likely involves tumour-associated immune complexes, has been described as a rare association with haematological malignancy.4 The achievement of disease remission led to resolution of both angio-oedema and urticarial vasculitis in our case.
 
Our patient demonstrated a kappa-restricted serum FLC with the summated FLC being 112 mg/L, confirming the monoclonal nature of serum FLC. Studies have shown that serum FLC may be elevated in almost 50% of patients with CLL. This finding is an adverse prognostic factor for time to treatment and overall survival.5
 
The mainstay of treatment for acute acquired angio-oedema includes C1 esterase inhibitor concentrate from human plasma or recombinant C1 inhibitor concentrate.3 Nonetheless these products are not widely available in most healthcare facilities, including our centre where fresh frozen plasma is a reasonable alternative, although not without potential risks. Long-term prophylactic treatment with antifibrinolytic agents and danazol has been shown to be equally efficacious,2 with a recommendation to avoid the former in the presence of thromboembolic risk factors.2 It is vital to treat the underlying disease to prevent acute attacks, regardless of the treatment options.2 Our patient has had no further attacks of angio-oedema after receiving rituximab, cyclophosphamide, vincristine, and prednisolone chemotherapy. This is in concordance with the literature that reports resolution of angio-oedema after treatment of the underlying malignancy.4
 
Our case highlights the challenge posed in managing a patient with CLL and atypical features. Clinical suspicion should be heightened in patients who present with recurrent episodes of angio-oedema. Treating the underlying malignancy often leads to complete resolution of symptoms.
 
Author contributions
Concept or design: ASO Tang, TS Leong, LP Chew.
Acquisition of data: ASO Tang, JTH Lee, QY Wong, ST Yeo.
Analysis or interpretation of data: JTH Lee, QY Wong, ST Yeo.
Drafting of the manuscript: ASO Tang, TS Leong, LP Chew.
Critical revision of the manuscript for important intellectual content: All authors.
 
Conflicts of interest
The authors declare that they have no conflict of interest or financial disclosure.
 
Acknowledgement
The authors would like to thank the Director General of Health Malaysia and Clinical Research Centre (CRC) Miri Hospital for permission to publish this paper.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
This article does contain studies with human participants and was registered via National Medical Research Register Malaysia with a Research ID of NMRR-20-1666-56020. The patient(s) provided written informed consent for all treatments and procedures and consent for publication.
 
References
1. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000;106:1147-54. Crossref
2. Gobert D, Paule R, Ponard D, et al. A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients. Medicine (Baltimore) 2016;95:e4363. Crossref
3. Cicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003;82:274-81. Crossref
4. Marder RJ, Rent R, Choi EY, Gewurz H. C1q deficiency associated with urticarial-like lesions and cutaneous vasculitis. Am J Med 1976;61:560-5. Crossref
5. Sarris K, Maltezas D, Koulieris E, et al. Prognostic significance of serum free light chains in chronic lymphocytic leukemia. Adv Hematol 2013;2013:359071. Crossref

Persistent fever in a child with eosinophilia and systemic symptoms: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Persistent fever in a child with eosinophilia and systemic symptoms: a case report
CS Wai, MB, ChB, MRCPCH; WF Hui, MB, ChB, MRCPCH; Karen KY Leung, MB, BS, MRCPCH; KL Hon, MB, BS, MD
Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong
 
Corresponding author: Dr KL Hon (ehon@hotmail.com)
 
 Full paper in PDF
 
Case
In October 2019, an 8-year-old girl with Diamond–Blackfan anaemia on long-term maintenance steroid therapy was admitted to a paediatric unit with meningitis. The meningitis was caused by extended spectrum beta-lactamase-producing Klebsiella pneumonia that was sensitive to meropenem but resistant to cephalosporin and penicillin group of antibiotics. She was treated with intravenous meropenem and her fever subsided.
 
On day 21 of meropenem treatment the patient’s fever recurred with temperature of 39.7°C and associated abdominal pain, diarrhoea, and rash (Fig 1). Physical examination revealed a generalised blanchable erythematous maculopapular rash over her face, torso, and limbs with no mucosal involvement or lymphadenopathy (Fig 2). She was tachycardic at 150 beats per minute but her blood pressure was normal. She was given fluid boluses and managed in the paediatric intensive care unit with a noradrenaline infusion (0.05 μg/kg/min), prednisolone (increased to 20 mg daily), and the addition of vancomycin.
 

Figure 1. Temporal relationship of antibiotic use and clinical parameters
 

Figure 2. An 8-year-old girl with meropenem-associated drug reaction with eosinophilia and systemic symptoms. Clinical photographs show rash over (a) torso, (b) face, and (c) limbs
 
Autoimmune disease and infection workup including serology for Epstein–Barr virus, cytomegalovirus, and human herpesvirus 6 and stool culture for ova, cysts, and parasites examination were all negative. The patient’s C-reactive protein level was 166.43 mg/L (normal range <10 mg/L) and procalcitonin was 3.63 ng/mL (normal range <0.5 ng/mL). There was evolving eosinophilia since fever recurrence. The absolute eosinophil count was elevated to 1.2×109/L (18.9% of total white cell count) on the first day of fever recurrence with a peak of 1.4×109/L (35.4% of total white cell count). Gamma-glutamyl transferase level was elevated (57 IU/L). Skin biopsy showed non-specific perivascular lymphocyte infiltration with no eosinophils. There was no erythema multiforme-like pattern, spongiosis, interface change or vasculitis and staining showed no fungus.
 
Meropenem-associated drug reaction with eosinophilia and systemic symptoms (DRESS) was suspected in view of her fever, rash, persistent eosinophilia, and deranged liver function alongside prolonged meropenem use and a negative infection workup. Meropenem was therefore stopped, and her fever subsided after 6 hours. She was also weaned off inotrope support. She remained hemodynamically stable and the rash did not worsen and gradually subsided in 48 hours. She was discharged from the paediatric intensive care unit 2 days later. There was no residual rash and eosinophil count had normalised 2 weeks after onset of DRESS symptoms.
 
Discussion
Children with fever and rashes pose challenges in diagnosis and management. Differential diagnoses must consider “drug versus bug” scenarios.1 Drug reaction with eosinophilia and systemic symptoms is a rare reaction to certain medications and involves a widespread skin rash, fever, swollen lymph nodes, and characteristic blood abnormalities including eosinophilia, thrombocytopenia and atypical lymphocytosis.2 Drug reaction with eosinophilia and systemic symptoms is classified as a form of severe cutaneous adverse reaction that usually develops within 6 weeks of initiation of the suspected drug.3 It may be associated with hepatitis, carditis, interstitial nephritis or interstitial pneumonitis and is potentially life-threatening with a reported mortality rate up to 10%.2 The estimated incidence of DRESS is 1 in 1000 to 1 in 10000 drug exposures and is more commonly observed in adults than children.4
 
The RegiSCAR (European Registry of Severe Cutaneous Adverse Reactions) developed a scoring system in 2007 to classify patients as having no, possible, probable, or definite DRESS based on clinical features and laboratory findings.5 Our patient had a score of 3 and was classified as possible DRESS, with extreme eosinophilia, rash with >50% body surface area involvement and negative microbiological investigations. One point was deducted from the score for “rash resolution more than 15 days”. Her aminotransferase and bilirubin level remained normal throughout although gamma-glutamyl transferase was elevated. Skin biopsy revealed perivascular lymphocytosis, a commonly observed feature among patients with DRESS.5 Skin biopsy is indicated as one of the parameters in RegiSCAR if facilities are available.
 
Carbapenems, as members of the beta-lactam antibiotics, are reported to pose a low risk of allergic reaction or DRESS. The incidence of rash, pruritis and urticaria after use of carbapenem has been reported to be only 0.3 to 3.7%, with rash reported in only 1.4% of patients treated with meropenem.6 Early suspicion of DRESS is crucial as discontinuation of the culprit drug can prevent development of potentially life-threatening complications. This case illustrates that all sepsis symptomatology subsided in a febrile patient with rash and eosinophilia, not by adding more drugs but by considering the possibility of severe cutaneous adverse reactions and removing the culprit drug.
 
Author contributions
All authors contributed to the concept or design of the study, acquisition of the data, analysis or interpretation of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
As an editor of the journal, KL Hon was not involved in the peer review process. Other authors have no conflicts of interest to disclose.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The patient was treated in accordance with the Declaration of Helsinki and a parent provided informed consent for all treatments and procedures. Consent was obtained from the patient and her parents for publication.
 
References
1. Hon KL, Choi CL. Steven Johnson syndrome: drug or bug? Indian J Pediatr 2016;83:1508-9. Crossref
2. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011;36:6-11. Crossref
3. Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol 2017;177:1234-47. Crossref
4. Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management Expert Opin Drug Saf 2017 2020;16:139-47.
5. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-80. Crossref
6. Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30:657-68. Crossref

Long-term tumour-treating fields for glioblastoma and beyond disease progression: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Long-term tumour-treating fields for glioblastoma and beyond disease progression: a case report
Peter YM Woo, MB, BS, FRCS1; TC Lam, MB, BS, FRCR2; Aya El Helali, MB, BCh, PhD2
1 Department of Neurosurgery, Kwong Wah Hospital, Hong Kong
2 Department of Clinical Oncology, The University of Hong Kong, Hong Kong
 
Corresponding author: Dr Peter YM Woo (wym307@ha.org.hk)
 
 Full paper in PDF
 
Case report
In May 2018, a 55-year-old Chinese man experienced sudden headache, vomiting and generalised seizures. On hospitalisation, he had a Glasgow Coma Score of 13/15 and global aphasia. Gadolinium contrast-enhanced magnetic resonance imaging revealed a left middle temporal gyrus heterogeneously enhancing intra-axial brain tumour with intratumoural haemorrhage (Fig 1a). A craniotomy for gross total tumour resection was performed under general anaesthesia 1 day after admission (Fig 1b). The patient fully recovered his language ability and was discharged from the hospital 3 days after surgery with no focal neurological deficit. At discharge, he had a Karnofsky Performance Score of 90 and an Eastern Cooperative Oncology Group (ECOG) performance status of 1. The histopathological diagnosis was glioblastoma (IDH-1 wildtype, promoter MGMT unmethylated). Targeted nextgeneration gene sequencing revealed the presence of CDKN2A homozygous deletion and EGFR amplification, molecular biomarkers associated with a poorer prognosis.1
 

Figure 1. (a) Preoperative axial magnetic resonance imaging: left temporal glioblastoma with intratumoural haemorrhage. (b) After concomitant temozolomide chemoradiotherapy and 5 months of tumour-treating fields (TTF). (c) First disease progression after 12 months of TTF. (d, e) TTF current density (Amp/cm2) and electric field intensity (V/cm) maps revealing increased electromotive force delivery to the peritumoural region after gross total resection of the patient’s first tumour recurrence. (f) No evidence of residual tumour 3 years after initial diagnosis and 30 months of TTF
 
The patient received concomitant temozolomide (TMZ) chemoradiotherapy with a total of 60 Gy of radiation given over 30 fractions. After three adjuvant cycles of TMZ, 6 months after diagnosis, alternating electric field therapy also known as tumour-treating fields (TTF) was started in December 2018. After initiation, the patient was able to return to work as a bartender with a Karnofsky Performance Score of 100 and ECOG status of 0. His mean monthly TTF compliance was 75% and although he experienced grade I scalp skin toxicity (mild dermatitis), this was resolved with topical hydrocortisone cream (Fig 2). The patient received a total of six cycles of TMZ and declined further chemotherapy, relying on TTF alone for tumour control for the next 12 months. His EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer global quality of life) score was 67/100 before TTF, which improved to 84/100 after 6 months. The caregiver stress index, a self-reported measure of primary caregiver burden, was 2 (a threshold of >7 indicates high stress).
 

Figure 2. Clinical photographs revealing grade I skin toxicity and its resolution after topical hydrocortisone cream treatment. Lateral views of the craniotomy wound after (a) 1 week, (b) 2 weeks, and (c) 8 weeks of tumour-treating fields; scalp vertex after (d) 1 week, (e) 2 weeks, and (f) 8 weeks of tumour-treating fields
 
There was focal tumour recurrence 18 months after diagnosis and a second craniotomy with supratotal resection was performed in December 2019 (Fig 1c). The patient received six cycles of second-line lomustine chemotherapy and TTF was restarted 6 weeks after the operation. The treatment field plan was adjusted after the second resection to enhance the current density (CD, Amp/cm2) and electric field intensity (EF, V/cm) to the peritumoural regions (Fig 1d and e). The patient’s monthly TTF compliance increased to 85% and his ECOG status was 1. After 14 months, in February 2021, there was a second glioblastoma recurrence at the inferior temporal gyrus located beyond the treatment EF50% and CD50% isodose regions. An awake craniotomy for language mapping and 5-aminolevulinic acid fluorescent-guided gross total resection was performed. Since the patient’s recurrent glioblastoma now had acquired TMZ and lomustine resistance, without effective third-line systemic therapy options, he was promptly restarted on TTF 2 weeks after surgery achieving a mean compliance of 90%. The patient received a further 10 months of TTF monotherapy after his second recurrence, experiencing minimal adverse effects with an ECOG performance status of 1, good quality of life (EORTC 89/100) and no recurrence (Fig 1f). In December 2021, multifocal disease progression with leptomeningeal spread was detected and the patient passed away in February 2022, 45 months (3.8 years) after diagnosis.
 
Discussion
Glioblastoma is the most common primary malignant brain tumour in adults with a prevalence of 3 to 5 per 100 000 population. In Hong Kong, 80 to 100 patients are diagnosed annually. Multimodality standard-of-care treatment has remained unchanged over the last 15 years comprising of maximal safe resection followed by concomitant TMZ chemoradiotherapy.2 Prognosis nonetheless remains poor and patients have a median overall survival (OS) of only 15 months and for those with an unmethylated pMGMT tumour molecular profile, 12 months.2 Tumour-treating fields is a novel therapy approved by the United States Food and Drug Administration and has been incorporated in several national guidelines as a first-line treatment option for patients with newly diagnosed glioblastoma. The therapy consists of the non-invasive local administration of alternating electric fields of low intensity (1-3 V/cm) and intermediate frequency (200 kHz) to the post-resection region. The mechanism of action involves the exertion of an electromotive force on intracellular proteins critical for mitosis, namely the microtubule substrates tubulin and septin. The antimitotic effect is most pronounced during the tumour cell cycle metaphase when microtubule assembly is disrupted, resulting in aneuploidy, post-mitotic stress, and ultimately apoptosis.3
 
The efficacy of TTF in glioblastoma is well supported by several randomised controlled trials. The landmark EF-14 phase III trial that recruited 695 patients with newly diagnosed glioblastoma revealed a significant increase in median OS among those who received TTF and standard TMZ chemoradiotherapy compared with their control group counterparts that received standard treatment alone (21 vs 17 months; hazard ratio=0.63; 95% confidence interval=0.53-0.76).3 The 2-year OS rate for patients receiving TTF with standard care was 43% compared with 29% for those that received standard care alone.3 These findings were independent of conventional predictors of OS such as pMGMT methylation status or extent of resection and were validated by subsequent studies. Our patient’s glioblastoma carried a relatively poor prognostic molecular profile and to observe his longer-than-expected OS demonstrates how TTF-generated antimitotic electromotive forces remain unaffected by tumour chemoresistance mechanisms. Studies have also documented a dose-response relationship whereby mean monthly treatment compliance, above a threshold of 60%, was associated with improved median OS.3 4 5 This phenomenon was also noted in our patient where his first progression-free survival was 12 months with 75% TTF compliance but subsequently increased to 14 months when his compliance was improved to 85%. In general, the median OS of patients with recurrent glioblastoma is 6.5 months and it is encouraging that our experience documented an additional survival benefit from TTF beyond first and second disease progression regardless of the systemic therapy prescribed.6 7
 
The only modifiable predictor for OS is the extent of glioblastoma resection8 and we believe this played an important role in our patient’s response to TTF. There is robust evidence that maximal safe resection, even beyond radiologically defined tumour boundaries (ie, supratotal resection), confers a significant advantage.9 To this end, awake craniotomy with intra-operative brain mapping and 5-aminolevulinic acid fluorescent guided resection have been proven to be useful surgical adjuncts.10 11 In contrast, standards of care for systemic treatment at recurrence are much less well-defined.7 12 Despite limited evidence to support its use, lomustine, a nitrosourea alkylating agent, is the most frequently administered second-line treatment.12 Randomised controlled clinical trials revealed lomustine treatment response rates to only be in the range of 10%, conferring a median progression-free survival of <2 months.12 13 Furthermore, lomustine activity is largely restricted to pMGMT methylated tumours, which our patient did not have.12
 
Starting in December 2018, Hong Kong was the first Asian region outside of Japan to provide patients with access to TTF. Treatment is generally started as early as 2 weeks after radiotherapy and patients are required to have their hair clipped during the entire period. The electric fields are delivered through disposable adhesive scalp transducer arrays connected to a portable generator with interchangeable batteries, each lasting for 4 hours. Dosimetry in terms of field intensity (V/cm) and current density (Amp/cm2) can significantly influence OS therefore array positioning requires an analysis of magnetic resonance imaging scans to achieve the greatest therapeutic effect (Fig 1).4
 
Scalp arrays are typically changed every 3 days when hair regrowth interrupts their apposition. Patients are required to be constantly connected to the 1.2-kg field generator for at least 15 hours per day. Despite this treatment commitment, reviews of the quality of life of TTF patients report outcomes comparable to those without such therapy.14 The most common adverse effect, occurring in up to 45% of patients, is scalp dermatitis, which is often mild to moderate in nature and sufficiently managed by temporary array repositioning or topical hydrocortisone.3 There is no evidence to suggest that patients receiving TTF are at higher risk of developing seizures. The only absolute contra-indications to TTF are the presence of a large skull defect, an active implantable medical device, uncontrolled scalp wound infection, or allergies to adhesive tape or hydrogels.
 
The TTF therapy is the first breakthrough treatment for glioblastoma in >15 years. As exhibited by our patient, long-term TTF therapy was well-tolerated and conferred a significant benefit in terms of OS.
 
Author contributions
Concept or design: PYM Woo, TC Lam.
Acquisition of data: PYM Woo, TC Lam.
Analysis or interpretation of data: PYM Woo, TC Lam.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (Ref No. UW 19-626). Patient consent available upon request.
 
References
1. Mirchia K, Richardson TE. Beyond IDH-mutation: emerging molecular diagnostic and prognostic features in adult diffuse gliomas. Cancers (Basel) 2020;12:1817. Crossref
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. Crossref
3. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017;318:2306-16. Crossref
4. Ballo MT, Urman N, Lavy-Shahaf G, Grewal J, Bomzon Z, Toms S. Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: a large-scale numerical simulation-based analysis of data from the phase 3 EF-14 randomized trial. Int J Radiat Oncol Biol Phys 2019;104:1106-13. Crossref
5. Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. J Neurooncol 2019;141:467-73. Crossref
6. Kesari S, Ram Z, EF-14 Trial Investigators. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncol 2017;6:185-93. Crossref
7. van Linde ME, Brahm CG, de Witt Hamer PC, et al. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol 2017;135:183-92. Crossref
8. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3-8. Crossref
9. Jackson C, Choi J, Khalafallah AM, et al. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol 2020;148:419-31. Crossref
10. Zhang JJ, Lee KS, Voisin MR, Hervey-Jumper SL, Berger MS, Zadeh G. Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis. Neurooncol Adv 2020;2:vdaa111. Crossref
11. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7:392-401. Crossref
12. Weller M, Le Rhun E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev 2020;87:102029. Crossref
13. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010;28:4601-8. Crossref
14. Taphoorn MJ, Dirven L, Kanner AA, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial. JAMA Oncol 2018;4:495-504. Crossref

Luxatio erecta of the hip in a 64-year-old man: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Luxatio erecta of the hip in a 64-year-old man: a case report
Kemal Gokkus, MD; Mehmet S Sahin, MD
Department of Orthopedics and Trauma, Baskent University Medical Faculty–Alanya Research and Practice Center, Turkey
 
Corresponding author: Dr Kemal Gokkus (kemalg@baskent.edu.tr)
 
 Full paper in PDF
 
Case report
In March 2021, a 64-year-old man who was injured in a fall was brought to our emergency department. He had lost his balance and fallen while harvesting avocados from a tree. He reported severe right hip and right lateral chest pain and was unable to move his right hip. His vital signs were unremarkable. He held his right hip in flexion and abduction (Fig 1a). The limb was neurologically intact and good distal arterial pulses were present. Plain anteroposterior radiograph of the pelvis revealed an inferior dislocation of the femoral head (Fig 1b).
 

Figure 1. (a) Clinical photograph showing the patient with right hip in flexion and abduction. This position of the lower limb is typical luxatio erecta of the hip (inferior dislocation of the hip). (b) Plain anteroposterior radiograph of the pelvis taken before reduction showing the femoral head dislocated inferiorly
 
Computed tomography (CT) scan of the chest (not shown) revealed an ipsilateral nondisplaced rib (8-10) and scapular spine fractures. A CT scan of the pelvis (Fig 2) demonstrated an empty acetabulum with no associated fractures. Later, the patient was brought to the operating theatre and 0.5 mg/kg propofol and 0.5 μg/kg remifentanil administered intravenously for the first 90 s. Thereafter, further doses of both propofol 0.25 mg/kg and remifentanil 0.25 μg/kg were administered. After 3 to 4 minutes the patient was adequately sedated and pain-free.
 

Figure 2. (a) Coronal and (b) axial computed tomography scans showing the empty acetabulum without associated fracture. Because the patient could not bring his hip into adduction, it was not possible to obtain an image at the level of the dislocation
 
The dislocation was reduced under sedation and fluoroscopy by manual traction in the line of deformity, initially followed by adduction of the femur, resulting in an uneventful reduction (Video 1). Fluoroscopy confirmed that the hip range of motion was safe after reduction; the hip was safe at 90° of flexion, 20° of adduction, 30° of abduction, and 30° of internal or external rotation.
 
After clinic follow-up the next day, the patient was discharged home and advised to remain on bed rest for 3 weeks, and to use a walker (with toe-touch weight-bearing) solely for going to the toilet.
 
To prevent heterotopic bone formation and thromboprophylaxis, 25-mg indomethacin orally 3 times daily and 0.4-mL enoxaparin sodium daily were prescribed for the first 2 weeks after surgery. The use of indomethacin for prophylaxis is well documented in the literature and its use to prevent heterotopic ossification following treatment for posterior hip dislocation with acetabular fractures has been reported by Mitsionis et al.1 Deep venous thrombosis has rarely been reported after an isolated hip dislocation.1 Nevertheless, indomethacin for prophylaxis was prescribed to our patient in view of the need for prolonged bed rest and his relatively advanced age.
 
At follow-up examination 3 weeks after reduction, the patient was able to bear weight with a mildly antalgic gait (Video 2). The observed antalgic gait prompted us to be more conservative so the patient was advised to avoid strenuous activity and to use crutches with partial weight-bearing. At the same visit, a post-reduction radiograph and CT scan was performed to rule out chip or flake fractures of the femoral head or acetabulum during reduction; if hip pain persists, a magnetic resonance imaging scan can be performed to look for evidence of a labral tear. No associated acetabular or femoral head fracture was observed (Fig 3). The patient will continue to be monitored for a year for possible aseptic necrosis and myositis ossificans.
 

Figure 3. Follow-up examination at 3 weeks after reduction of the hip dislocation. (a, b) Plain anteroposterior radiographs of the pelvis showing concentric reduction without concomitant acetabular or femoral head fracture. (c) Coronal and (d) axial computed tomography scans showing no associated acetabular or femoral head fracture
 
Discussion
There are two types of inferior hip dislocation: obturator and ischial. Parvaresh et al2 analysed acetabular development and concluded that between the ages of 12 and 16, the three ossification centres and triradiate cartilage are ossified in both sexes. It is realistic then to consider it an adult hip if the patient is >16 years.2 Few cases of inferior (ischial type) hip dislocation have been reported. We reviewed the English-language literature search and found only five reported cases of inferior hip dislocation in adult patients (age >16 years).3 4 5 6 7 Among them, our patient is the oldest case reported with uneventful reduction.
 
Traumatic hip dislocation can cause complications that include avascular necrosis (6%-27% for early closed reduction), post-traumatic osteoarthritis (17%-48%), heterotopic ossification (up to 32%),1 8 and sciatic nerve injury (approximately 10%).9 To avoid complications, early and uneventful reduction is critical. In our patient, reduction was achieved within 2 hours of initial presentation. Our patient may be the only case documented with radiographic imaging performed before and after the reduction (including CT) and video of the reduction manoeuvre and a clinical video of the patient (demonstrating the patient walking in the third week after the reduction).
 
Brogdon and Woolridge10 described the mechanism of ischial and obturator injury. In the ischial type, the person falls on the trunk with the hip flexed and lands on the flexed knee. The accumulated force from further flexion of the upper trunk and body weight may create the momentum to push the femoral head inferiorly through the shallow and relatively rimless inferior margin of the acetabulum. Treatment consists of closed reduction under sedation or general anaesthesia with axial traction, together with gradual extension of the femur with additional internal rotation manoeuvres.9
 
The common obturator type of dislocation occurs when the femur is physically abducted and twisted outwards when the patient slips or when another force is applied. If the forcible abduction and external rotation continue with flexion against the pelvis, the femur is levered anteriorly out of the acetabulum. Treatment comprises closed reduction under sedation/general anaesthesia with longitudinal traction in the direction of the femoral axis and gentle adduction and flexion of the hip with additional internal rotation manoeuvres.10
 
There is a strong consensus in the literature that CT examination be performed prior to reduction to assess a probable acetabular wall fracture or head split fracture of the femoral head.8 In the present case, we could not complete all markings on the CT scan because the abducted hip automatically blocked the CT platform. Fortunately, we evaluated the anterior and posterior acetabular walls and confirmed no remnants in the acetabular fossa nor any fractures on the acetabular walls. Based on the reduction and stability confirmed by physical examination after the reduction, radiographic examination after reduction and CT was postponed until 3 weeks after reduction, when the patient was allowed to fully weight bear for the first time.
 
Inferior hip dislocation is rare and can be successfully treated with closed reduction. Orthopaedic surgeons must be able to diagnose and optimally treat this type of dislocation. This report and videos serve as a teaching tool for this reduction manoeuvre.
 
Author contributions
Concept or design: Both authors.
Acquisition of data: Both authors.
Analysis or interpretation of data: Both Gokkus.
Drafting of the manuscript: K Gokkus.
Critical revision of the manuscript for important intellectual content: All authors.
 
Both authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
Both authors have no conflicts of interest to disclose.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The patient was treated according to the principles of the Declaration of Helsinki. The patient provided informed consent for all treatments, procedures, and consent for publication.
 
References
1. Mitsionis GI, Lykissas MG, Motsis E, et al. Surgical management of posterior hip dislocations associated with posterior wall acetabular fracture: a study with a minimum follow-up of 15 years. J Orthop Trauma 2012;26:460-5. Crossref
2. Parvaresh KC, Pennock AT, Bomar JD, Wenger DR, Upasani VV. Analysis of acetabular ossification from the triradiate cartilage and secondary centers. J Pediatr Orthop 2018;38:e145-50. Crossref
3. Kolar MK, Joseph S, McLaren A. Luxatio erecta of the hip. J Bone Joint Surg Br 2011;93:273. Crossref
4. Singh R, Sharma SC, Goel T. Traumatic inferior hip dislocation in an adult with ipsilateral trochanteric fracture. J Orthop Trauma 2006;20:220-2. Crossref
5. Walther MM, McCoin NS. Luxatio erecta of the hip. J Emerg Med 2013;44:985-6. Crossref
6. Tekin AÇ, Çabuk H, Büyükkurt CD, Dedeoğlu SS, İmren Y, Gürbüz H. Inferior hip dislocation after falling from height: a case report. Int J Surg Case Rep 2016;22:62-5. Crossref
7. Zeytin AT, Kaya S, Kaya FB, Ozcelik H. Traumatic inferior hip dislocation. J Med Cases 2015;6:238-9. Crossref
8. Yang RS, Tsuang YH, Hang YS, Liu TK. Traumatic dislocation of the hip. Clin Orthop Relat Res 1991;(265):218-27. Crossref
9. Cornwall R, Radomisli TE. Nerve injury in traumatic dislocation of the hip. Clin Orthop Relat Res 2000;(377):84-91.Crossref
10. Brogdon BG, Woolridge DA. Luxatio erecta of the hip: a critical retrospective. Skeletal Radiol 1997;26:548-52. Crossref

Clinical and molecular features of pleuropulmonary blastoma in children in Hong Kong: case reports

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Clinical and molecular features of pleuropulmonary blastoma in children in Hong Kong: case reports
Anthony PY Liu, MB, BS1; Marcus KL Fung, PhD1; Mianne Lee, MSc1; Jasmine LF Fung, BSc1; Mandy HY Tsang, MMedSc1; CW Luk, MB, BS2; Brian HY Chung, MB, BS, MD1; Godfrey CF Chan, MD1
1 Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
2 Department of Paediatrics and Adolescent Medicine, Hong Kong Children’s Hospital, Hong Kong
 
Corresponding author: Prof Godfrey CF Chan (gcfchan@hku.hk)
 
 Full paper in PDF
 
Case report
Patient 1
In January 1998, a 14-month-old girl presented with fever and dyspnoea. Plain chest radiograph showed opacification of the right hemithorax that corresponded to a multicystic mass on computed tomography. Thoracotomy was performed and a 11-cm × 9.5-cm × 5-cm mixed cystic-solid mass excised. Together with histological findings, type II pleuropulmonary blastoma (PPB) was diagnosed. The patient was treated with adjuvant chemotherapy according to the Intergroup Rhabdomyosarcoma Study-IV regimen but developed ifosfamide-induced renal tubulopathy. At the time of writing, the patient remains in remission (age 23 years). Sanger sequencing revealed no DICER1 mutation in the patient’s peripheral blood DNA.
 
Patient 2
In November 2008, a 9-month-old girl presented with progressive dyspnoea. Plain chest radiograph revealed left-sided pneumothorax. Computed tomography scan of the thorax after thoracocentesis revealed a 3-cm cystic lesion in the lingula, suspicious of congenital cystic adenomatoid malformation. In view of the risk of recurrent pneumothorax, left upper lobectomy was performed. Microscopically, features of the excised lesion were compatible with type I PPB. No adjuvant treatment was required and the patient remained in remission for 10 years. Multinodular goitre (MNG) was also diagnosed at age 7 years. Sanger sequencing of the patient’s peripheral blood DNA revealed a heterozygous frameshift mutation in DICER1 (NM_177438.2:c.4022del(p.(Gly1341Alafs*6)); Fig 1), inherited from her father (Fig 2), who also had a history of MNG with thyroidectomy done. Familial counselling was offered with discussion about the role of further cascade testing and recommendations for surveillance.
 

Figure 1. Sanger sequencing indicating germline DICER1 mutation in the proband of Case 2
 

Figure 2. Sanger sequencing indicating germline DICER1 mutation in the father of Case 2
 
Patient 3
In December 1999, a 2-year-old girl presented with presumed right-sided pneumonia unresolved for 2 months. Computed tomography scan of the thorax showed collapse-consolidation with pleural effusion. Exploratory thoracotomy revealed a huge mass in the right middle lobe and debulking was performed. Histology confirmed type II PPB. A new computed tomography scan of the thorax demonstrated a residual multiloculated cystic mass with intermixed solid components. Adjuvant chemotherapy based on the Intergroup Rhabdomyosarcoma Study-IV regimen was adopted. Right middle lobectomy was performed after week 8 of chemotherapy. The patient subsequently developed cerebral relapses at age 7 years and again at age 17 years for which she was treated with excision and chemoradiotherapy (ifosfamide/carboplatin/etoposide + 40-Gy focal radiotherapy and irinotecan/temozolomide + 40-Gy focal radiotherapy, respectively). At the time of writing, the patient (age 21 years) has been in remission for 4 years. Multinodular goitre was also diagnosed at age 13 years. A heterozygous frameshift mutation in DICER1 was detected in the patient’s peripheral blood using Sanger sequencing (NM_17 7438.2:c.1651_1654delGGAA(p(Gly551Glufs*10)); Fig 3).
 

Figure 3. Sanger sequencing indicating germline DICER1 mutation in proband of Case 3
 
Patient 4
In January 2016, a 2-year-old girl presented with fever, cough and progressive dyspnoea. Computed tomography of the thorax revealed a large space-occupying lesion in the right thoracic cavity, with pleural effusion, mediastinal shift and superior vena cava compression. Biopsy confirmed type III PPB. Considering the risk of upfront surgery, neoadjuvant chemotherapy with ifosfamide, vincristine, actinomycin and doxorubicin was started. Unfortunately her response was suboptimal and she developed respiratory embarrassment and required emergency surgery during which she went into cardiopulmonary arrest. Despite successful resuscitation and debulking surgery, the patient demonstrated signs of severe hypoxic ischaemic encephalopathy. In view of the poor neurodevelopmental prognosis, the family elected to continue only palliative care. The patient eventually succumbed to progression 6 months after diagnosis. Sanger sequencing of peripheral blood DNA showed a nonsense mutation on exon 7 of DICER1 (NM_177438.2:c.1174C>T, p.R392*; Fig 4); her father tested negative for the same germline mutation and her mother was not available for evaluation.
 

Figure 4. Germline DICER1 mutation spectrum on genomic DNA of patients with pleuropulmonary blastoma with reference data from the Human Gene Mutation Database (https://www.hgmd.cf.ac.uk/), a recent report on Chinese patients with pleuropulmonary blastoma4 (underlined text) and our results of Cases 2, 3, and 4 (bold text). NM_177438.2 was used as the reference sequence for DNA bases. The amino acid numbering used begins with the Kozak consensus sequence. *: stop codon
 
Discussion
Pleuropulmonary blastoma is a rare thoracic tumour that arises during infancy or young childhood.1 Its aggressiveness and presenting features vary according to the histological subtype, ranging from the self-limiting cystic form (type I) with potential to undergo spontaneous regression (type Ir) or the mixed cystic/solid form (type II) that would benefit from adjuvant cytotoxic treatment, to a solid form (type III) that carries a considerable risk of disease relapse despite multimodal therapy. As an entity originally designated in 1988, familial clustering of PPB was first reported in 1996. This led to the recognition of underlying germline DICER1 alterations, and subsequently the definition of DICER1 syndrome—an autosomal dominant condition with variable penetrance and associated with almost 30 neoplastic conditions, including MNG, cystic nephroma, and ovarian stromal tumours.2 The oncogenic mechanism consequent to DICER1 mutations is hypothesised to be related to the resulting imbalance of mature miRNAs derived from the 5′ and 3′ ends of the precursor pre-miRNA. Because of its rarity, data on the presentation and molecular features of patients with PPB in Chinese are limited and that in Hong Kong have never been reported.
 
We reviewed a territory-wide paediatric oncology database and report the various presenting features and clinical course of four patients with PPB treated between 1998 and 2020. Type I/type Ir PPB should be considered in cases of cystic lung lesions; while many represent as incidental findings, the risk of pneumothorax remains a concern for peripherally located lesions. Among those where resection has been performed, 90% will remain progression-free without the use of adjuvant chemotherapy.1 Type II and III PPB are differential diagnoses for young children (age <6 years) who present with a space-occupying thoracic mass or apparent, persistent chest infection. The surgical and perioperative management of massive lung lesions with mediastinal compression carries a high-risk of cardiovascular compromise and necessitates care at a tertiary referral centre with available expertise including extracorporeal membrane oxygenation support. For adjuvant therapy, the addition of doxorubicin to ifosfamide, vincristine and actinomycin has been shown to be efficacious in Types II/III PPB.3 However, half of these patients still develop progression by age 5 years, 60% with a central nervous system component.
 
The prevalence of germline pathogenic DICER1 mutations in the general population is estimated to be 1:10 600 in the ExAC-nonTCGA (The Cancer Genome Atlas) database, although mutations have been identified in two-thirds of patients with PPB with thus far a lack of genotype-phenotype correlation. In our series, novel heterozygous germline DICER1 frameshift mutations were found in cases 2 and 3; while a heterozygous germline nonsense mutation, reported recently in another Chinese patient, was detected in Case 4 (Fig 4).4 The findings of our case series add to the spectrum of known DICER1 mutations, especially to the very limited data from Asia.4 Diagnosing DICER1 syndrome facilitates surveillance of associated morbidities, familial testing and reproductive counselling for both probands and symptomatic carriers.5 Further studies and consideration of a prospective patient registry to define the prevalence of DICER1-associated conditions in both paediatric and adult populations in Hong Kong are warranted.
 
Author contributions
Concept or design: APY Liu, MKL Fung, BHY Chung, GCF Chan.
Acquisition of data: All authors.
Analysis or interpretation of data: APY Liu, MKL Fung, M Lee, JLF Fung.
Drafting of the manuscript: APY Liu, MKL Fung.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Acknowledgement
We would like to thank the patients and family for their consent to this study.
 
Funding/support
This study was supported by The Society for the Relief of Disabled Children. The funder had no role in study design, data collection/analysis/interpretation or manuscript preparation.
 
Ethics approval
This study was approved by the Institutional Review Board of the University of Hong Kong (Ref No. UW12-211) with informed consent obtained from patient guardians.
 
References
1. Messinger YH, Stewart DR, Priest JR, et al. Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer 2015;121:276-85. Crossref
2. de Kock L, Wu MK, Foulkes WD. Ten years of DICER1 mutations: provenance, distribution, and associated phenotypes. Hum Mutat 2019;40:1939-53. Crossref
3. Doros LA, Schultz KA, Harris A, et al. IVADo treatment of type II and type III pleuropulmonary blastoma (PPB): a report from the International PPB Registry. J Clin Oncol 2014;32(15 Suppl):10060. Crossref
4. Cai S, Wang X, Zhao W, Fu L, Ma X, Peng X. DICER1 mutations in twelve Chinese patients with pleuropulmonary blastoma. Sci China Life Sci 2017;60:714-20. Crossref
5. Schultz KA, Williams GM, Kamihara J, et al. DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies. Clin Cancer Res 2018;24:2251-61. Crossref

Candida glabrata fungal ball cystitis is a rare complication of conservative treatment of placenta accreta: a case report

© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
CASE REPORT
Candida glabrata fungal ball cystitis is a rare complication of conservative treatment of placenta accreta: a case report
CK Wong, MB, ChB1; LY Cho, MB, BS, FHKAM (Obstetrics and Gynaecology)1; WL Lau, MB, BS, FHKAM (Obstetrics and Gynaecology)1; Ingrid YY Cheung, MB, ChB, FHKAM (Pathology)2; Chloe HT Yu, MB, BS3; IC Law, MB, BS, FHKAM (Surgery)3; WC Leung, MD, FHKAM (Obstetrics and Gynaecology)1
1 Department of Obstetrics and Gynaecology, Kwong Wah Hospital, Hong Kong
2 Department of Pathology, Kwong Wah Hospital, Hong Kong
3 Department of Surgery, Kwong Wah Hospital, Hong Kong
 
Corresponding author: Dr CK Wong (wongchunkitjack@hotmail.com)
 
 Full paper in PDF
 
Case report
In October 2019, a 42-year-old pregnant woman was admitted to hospital at 35+2 weeks of gestation for an elective caesarean section because of anterior placenta praevia type I and suspected placenta accreta. She was gravida 6 and parity 3+2. Her first pregnancy in 1996 resulted in a normal vaginal delivery. The second and third pregnancies were surgically terminated in the first trimester. Fourth and fifth pregnancies resulted in a lower segment caesarean section in China due to oligohydramnios and previous caesarean section.
 
The patient had an uneventful antenatal course in the current pregnancy. Nonetheless ultrasound examination at 35+2 weeks of gestation revealed an anterior placenta praevia type I with the placenta’s leading-edge 2.7 cm from the os. A diagnosis of placenta accreta was made due to vascularities over the subserosal surface of the lower segment.
 
A classical caesarean section was performed after completing a course of antenatal corticosteroid at 36+4 weeks of gestation. Around four-fifths of the placenta separated spontaneously after 30 minutes. The placenta was trimmed away and 3 × 3 cm of anterior adherent placenta around the internal os was left in place. Active bleeding from the lower segment of the uterus and anterior placental bed was controlled with Sengstaken–Blakemore balloon tamponade (Rüsch Teleflex, Germany). Uterine artery embolisation was performed at the same operation by interventional radiologists. Total blood loss for the operation was 500 mL.
 
After surgery, the patient was transferred to the intensive care unit. Balloon tamponade was removed on day 1 (Fig 1). Prophylactic amoxicillin and clavulanate was administered intravenously after the operation. She complained of dysuria and developed a persistent swinging fever from day 2. Amoxicillin and clavulanate was switched to piperacillin/tazobactam on day 4 after blood and urine tests for sepsis. Culture of midstream urine showed Morganella morganii sensitive to piperacillin/tazobactam and a gram-negative bacillus. Microbiologists advised continuation of piperacillin/tazobactam for 7 to 10 days.
 

Figure 1. Timeline of patient treatment
 
Examination under anaesthesia and ultrasound-guided suction evacuation were performed on day 14 due to increased per-vaginal bleeding. Intra-operatively, yellowish pus was seen leaking from the cervical os and retained product of gestation weighing 48 g was retrieved. Culture of the pus grew Escherichia coli sensitive to piperacillin/tazobactam. The patient again presented with fever postoperatively and blood culture revealed E coli septicaemia. Piperacillin/tazobactam was switched to meropenem on day 17. Blood culture sensitivity testing revealed E coli sensitive to meropenem and cefuroxime. Hence, meropenem was switched to cefuroxime. Ultrasound examination on day 24 revealed no evidence of retained product of gestation. Cefuroxime was continued for 14 days.
 
At 5-week follow-up examination, the patient reported a 1-week history of whitish debris in her urine, dysuria, and urinary frequency. Ultrasonography revealed incomplete emptying of the bladder with a lot of frothy shadows (Fig 2a). Urinary tract infection was suspected so amoxicillin and clavulanate and phenazopyridine were prescribed for 1 week. Culture of the midstream urine showed Candida glabrata (Fig 2b). A microbiologist was consulted and fluconazole 400 mg prescribed for 10 days.
 

Figure 2. (a) Ultrasonograph showing “fungal debris” inside the bladder. (b) Photograph of Candida glabrata colony on CHROMagar Candida agar
 
Susceptibility testing of the C glabrata isolated from urine collected after admission was performed by using Sensititre YeastOne (TREK Diagnostic Systems, United Kingdom) and revealed a required fluconazole minimal inhibitory concentration of 16 μg/mL, confirming that it was in the susceptible-dose dependent category. However, the patient’s symptoms persisted after completing 24 days of fluconazole and ultrasound showed persistent “fungal debris” inside the bladder. She was readmitted 13 weeks after the operation for further management. Amphotericin B deoxycholate was administered intravenously for 7 days. A drug-related fever developed during the first dose but resolved after premedication with oral acetaminophen and intravenous diphenhydramine.
 
Flexible cystoscopy revealed necrotic tissue approximately 3 × 4 cm over the left posterior bladder wall, away from the left ureteric orifice, with an underlying ulcer (Fig 3a and b). It was removed with forceps and a basket. A fistula was suspected, and second flexible cystoscopy scheduled 2 months later. A computed tomography urogram with contrast was arranged to exclude fistula.
 

Figure 3. Cystoscopy images showing (a) necrotic tissue (b) and an ulcer over the bladder wall. (c) Second cystoscopy image taken 2 months later showing the healed ulcer
 
The second flexible cystoscopy revealed a normal bladder and a healed ulcer over the left posterior wall (Fig 3c). Computed tomography urogram showed no evidence of fistula. During postnatal follow-up, there were no urinary symptoms.
 
Discussion
This is the first case of C glabrata cystitis as a complication in our case series of planned conservative management of placenta accreta.1 Candida species are a part of the normal flora of the gastrointestinal and vaginal tracts. The incidence of candiduria has been increasing in recent decades and the presence of C glabrata has become clinically significant due to its high resistance to routine antifungal agents. Risk factors for candiduria in our case included urinary catheterisation, intensive care unit stay, use of broad-spectrum antibiotics, female sex, and prior surgery.2
 
The placental remnants in our case induced infection and septicaemia. Subsequent prolonged use of broad-spectrum antibiotics predisposed our patient to fungal cystitis. There was no clinical or pathological evidence of placenta percreta. Chandraharan et al3 introduced the use of the Triple-P procedure to manage patients with morbidly adherent placenta. As the Triple-P procedure removes all intrauterine placental remnants, it may reduce the risk of intrauterine infection and sepsis. Nevertheless, there is limited surgical expertise in this procedure in our unit.
 
Compared with other Candida species, many C glabrata isolates are resistant to azoles due to efflux pump–mediated resistance, genetic alterations under stress and biofilm protection.4 A study in the United States revealed that 14% of C glabrata isolates were resistant to fluconazole.5
 
The presence of fungus ball/fungal bezoars in urinary tract infection is extremely rare in adults. According to treatment guidelines of the Infectious Diseases Society of America, removal of the obstructing mycelial mass by surgical or endoscopic means is strongly recommended.6 Although culture results revealed that the C glabrata was susceptible-dose-dependent to fluconazole, use of fluconazole alone was likely to be insufficient due to the fungal ball in the bladder. A multidisciplinary approach including microbiologists and urologists is essential.
 
In symptomatic Candida cystitis, first-line treatment is oral fluconazole 200 mg daily for 2 weeks. For fluconazole-resistant C glabrata, amphotericin B deoxycholate or oral flucytosine are the drugs of choice. Around 50% of patients prescribed an amphotericin B infusion experience infusion-related adverse events, such as fever, chills, rigors, hypotension, and rarely, hypokalaemia resulting in ventricular fibrillation. In addition, renal toxicity is a well-known adverse effect.5 Close monitoring of renal function and electrolytes is essential.
 
Placenta accreta spectrum treated conservatively by leaving the placenta in situ is a recognised and successful management option, but is associated with risks of infection or postpartum haemorrhage. Our case demonstrates that fungal infection can develop during the period of conservative management and requires multidisciplinary consultation.
 
Author contributions
Concept or design: CK Wong, WC Leung.
Acquisition of data: All authors.
Analysis or interpretation of data: All authors.
Drafting of the manuscript: CK Wong, WC Leung.
Critical revision of the manuscript for important intellectual content: All authors.
 
Conflicts of interest
The authors have no conflicts of interest to disclose.
 
Acknowledgement
The authors thank interventional radiologists Dr KH Lee and Dr CW Tang for their contributions to this report.
 
Funding/support
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The patient was treated in accordance with the Declaration of Helsinki, provided informed consent for all treatments and procedures, and provided consent for publication.
 
References
1. Lo TK, Yung WK, Lau WL, Law B, Lau S, Leung WC. Planned conservative management of placenta accreta—experience of a regional general hospital. J Maternal Fetal Neonatal Med 2013;27:291-6. Crossref
2. Gajdács M, Dóczi I, Ábrók M, Lázár A, Burián K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. Cent European J Urol 2019;72:209-14.
3. Chandraharan E, Rao S, Belli A, Arulkumaran S. The Triple-P procedure as a conservative surgical alternative to peripartum hysterectomy for placenta percreta. Int J Gynecol Obstet 2012;117:191-4. Crossref
4. Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis 2013;33:673-88. Crossref
5. Pfaller MA, Messer SA, Hollis RJ, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009;47:3185-90. Crossref
6. Pappas PG, Kauffman CA, Andes DR, et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62:409-17. Crossref

Pages